Table 1 Clinical characteristics of the cohort at baseline
Characteristics | Values |
|---|---|
Age, mean (S.D.) years | 47.9 (13.7) |
Female sex, n/N (%) | 28/31 (90.3) |
Caucasian race, n/N (%) | 30/31 (96.8) |
Disease duration, mean (S.D.) years | 14.1 (8.0) |
Age of SLE onset, mean (S.D.) years | 33.8 (13.5) |
BMI, mean (S.D.) kg/m2 | 29.8 (8.1) |
Osteopaenia/osteoporosis, n/N (%) | 8/31 (25.8) |
Anti-phospholipid syndrome, n/N (%) | 3/31 (9.7) |
Current prednisolone, n/N (%) | 7/31 (22.6) |
Current hydroxychloroquine, n/N (%) | 18/31 (58.1) |
Current azathioprine, n/N (%) | 5/31 (16.1) |
Current methotrexate, n/N (%) | 4/31 (12.9) |
Current calcium supplementation, n/N (%) | 11/31 (35.5) |
Current vitamin D supplementation, n/N (%) | 11/33 (35.5) |
SLEDAI-2K, median (range) | 4 (0–11) |
SDI, median (range) | 0 (0–3) |